Crispr Therapeutics (NASDAQ:CRSP) was upgraded by equities research analysts at TheStreet from a “d+” rating to a “c” rating in a report released on Friday.
A number of other equities analysts also recently weighed in on the stock. SunTrust Banks upgraded shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Zacks Investment Research cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. BidaskClub raised shares of Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 25th. Citigroup lifted their price objective on shares of Crispr Therapeutics from $20.00 to $51.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 28th. Finally, Piper Jaffray Companies initiated coverage on shares of Crispr Therapeutics in a research report on Friday, December 22nd. They set an “overweight” rating for the company. Five analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $53.53.
Crispr Therapeutics stock opened at $51.52 on Friday. The firm has a market cap of $2,431.95, a price-to-earnings ratio of -29.95 and a beta of 3.63. Crispr Therapeutics has a fifty-two week low of $13.50 and a fifty-two week high of $61.24.
In other Crispr Therapeutics news, insider Tyler Dylan-Hyde sold 66,000 shares of Crispr Therapeutics stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $28.03, for a total transaction of $1,849,980.00. Following the completion of the transaction, the insider now directly owns 25,204 shares of the company’s stock, valued at $706,468.12. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Aktiengesellschaft Bayer acquired 527,472 shares of Crispr Therapeutics stock in a transaction on Friday, January 5th. The shares were bought at an average cost of $22.75 per share, with a total value of $11,999,988.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 283,850 shares of company stock valued at $7,261,865. Company insiders own 39.98% of the company’s stock.
Several institutional investors have recently made changes to their positions in CRSP. Wells Fargo & Company MN boosted its position in shares of Crispr Therapeutics by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after acquiring an additional 6,560 shares during the period. Vanguard Group Inc. bought a new stake in shares of Crispr Therapeutics in the second quarter valued at about $273,000. Ark Investment Management LLC bought a new stake in shares of Crispr Therapeutics in the second quarter valued at about $206,000. New York State Common Retirement Fund bought a new stake in shares of Crispr Therapeutics in the third quarter valued at about $344,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Crispr Therapeutics in the third quarter valued at about $288,000. 26.61% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Crispr Therapeutics (CRSP) Raised to C at TheStreet” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/03/20/crispr-therapeutics-crsp-raised-to-c-at-thestreet.html.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.